SOURCE: Business Review USA

Business Review USA

April 21, 2011 19:26 ET

Dr. David Mazzo, CEO of Regado Biosciences, Speaks on Developing New Products to Treat Cardiovascular Challenges in Antithrombosis in Business Review USA

SAN DIEGO, CA--(Marketwire - Apr 21, 2011) - In a report in Business Review USA, Dr. David Mazzo, CEO of Regado Biosciences, speaks on how the company is pioneering new therapeutic technology to develop controllable aptamer drugs.

Regado Biosciences, Inc. was founded in 2003 and is a privately-held company focused on developing new products to treat cardiovascular challenges in antithrombosis in surgery and other related procedures. The biopharmaceutical company is pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.

Regado Biosciences produces acute care products, not to be confused with oral chronic products, for hospitals and catheter laboratories. "The technology is based upon the very simple and elegant use of aptamers, which are oligonucleotides that have an affinity for specific biological targets and whose effects can be reversed using a complementary oligonucleotide that we developed in concert with the therapy," says Dr. David J. Mazzo, President and CEO of Regado Biosciences. "We have anticoagulation/antithrombotic pairs of drugs that work together -- one that produces the antithrombosis and the other that is a modulator that allows the physician to reverse either completely or partially the therapeutic effect of the first."

Read the full article, here.

About Regado Biosciences, Inc.:

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care setting. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

About Business Review USA

Business Review USA is a leading digital media source of news and content for C-level executives focused on business and industry-specific news throughout the United States. Business Review USA is the territory-dedicated arm of the White Digital Media Group. Founded in 2007 by entrepreneur Glen White, White Digital Media retains a diversified portfolio of websites, magazines, daily news feeds and weekly e-newsletters that leverage technology to innovatively deliver high-quality content, analytical data, and industry news.

Business Review USA is headquartered in San Diego, California, with an additional office in Boston. For more information, contact 1-760-827-7800 or visit http://www.BusinessReviewUSA.com.

Contact Information

  • Press Contact
    Nadia Ibanez
    Business Review USA
    Telephone: (760) 827-7151
    Email: n.ibanez@whitedm.com